Skip to content
OpenCapital
Get started

AbCellera Biologics Inc. ABCL Pre-tax stock-based compensation cost

Other financials

Income statement

See full
Revenue$8.3M+96.3%
Operating income-$57.5M+8.2%
Net income-$43.2M+5.4%
EPS (diluted)-$0.14+6.7%

Balance sheet

See full
Cash & equivalents$102.1M-44.6%
Total debt$140.2M+107%
Total equity$938.1M-8.3%
Total assets$1.3B-2.8%

Cash flow

See full
Operating cash flow-$33.5M-190%
CapEx$3.8M-64.0%
Free cash flow-$37.4M-68.3%

Valuation

See full
Market cap$1.84B+59.2%
Enterprise value$1.88B+100.0%
P/S23.3×-26.8×

Profitability

See full
Operating margin-267.6%-120pp
Net margin-181.7%-77.9pp
FCF margin-238.9%-90.9pp

Returns & leverage

See full
Return on equity-14.7%-0.8pp
Debt / equity0.1×+0.1×
Current ratio14.1×+3.9×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbCellera Biologics Inc.'s pre-tax stock-based compensation cost.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AbCellera Biologics Inc.'s pre-tax stock-based compensation cost?
AbCellera Biologics Inc. (ABCL) reported pre-tax stock-based compensation cost of $12.01M in Q1 2026.
How has AbCellera Biologics Inc.'s pre-tax stock-based compensation cost changed year-over-year?
AbCellera Biologics Inc.'s pre-tax stock-based compensation cost decreased by 18.8% year-over-year, from $14.79M to $12.01M.
What is the long-term trend for AbCellera Biologics Inc.'s pre-tax stock-based compensation cost?
Over 2 years (2023 to 2025), AbCellera Biologics Inc.'s pre-tax stock-based compensation cost has grown at a -6.8% compound annual growth rate (CAGR), from $64.18M to $55.79M.